ENTA News and Press, Enanta Pharmaceuticals Inc. From 06/21/22

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, announced today that it has filed suit in United States District Court for the District of Massachusetts ag...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s internal development program portfolio for hepatitis B virus (HBV) and it...

Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceu...

Enanta Pharmaceuticals (NASDAQ:ENTA) stock has lost 6.2% to $45.97 in Wednesday aftermarket trade, after the clinical-stage biotech said its phase 2b study evaluating its inhibitor EDP-938 in adults with respiratory syncytial virus (RSV) did not meet its main goal. The main goa...

Study Did Not Meet Primary Endpoint of Clinical Symptom Reduction or Secondary Antiviral Endpoints Statistically Significant Percent of Subjects Who Received EDP-938 Achieved Undetectable RSV RNA at End of Treatment EDP-938 was Safe and Well-Tolerated EDP-938...

Enanta's pipeline is stuffed with mid-stage RSV therapies and other earlier-stage programs. Enanta is one of many little biotechs which has a cash cow that can't keep up. Enanta has a solid balance sheet and a strong albeit recently stressed share price. For further details ...

Image source: The Motley Fool. Enanta Pharmaceuticals (NASDAQ: ENTA) Q2 2022 Earnings Call May 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals (ENTA) Q2 2022 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2022 Earnings Conference Call May 9, 2022, 04:30 PM ET Company Participants Jennifer Viera - Director of IR & Corporate Communications Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - Consultant Tara Kieffer - SVP, New Product Strategy...

Enanta Pharma press release (NASDAQ:ENTA): Q2 GAAP EPS of -$1.63 misses by $0.20. Revenue of $18.72M (-7.0% Y/Y) misses by $1.95M. For further details see: Enanta Pharma GAAP EPS of -$1.63 misses by $0.20, revenue of $18.72M misses by $1.95M

Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter Received Fast Track Designation for EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19; Expe...